Neutralization of Human Extrinsic (Tissue-Type) Plasminogen Activator in Human Plasma: No Evidence for a Specific Inhibitor

Summary

Human extrinsic plasminogen activator (EPA), highly purified from a melanoma cell culture fluid is inactivated in human plasma with a half-life (t ½) of 90–105 min. Gel filtration on Ultrogel AcA 34 of mixtures of ¹²⁵I-labeled EPA and human plasma, incubated at 37°C, revealed the progressive formation of two radioactive components, one with an apparent M_r of 150,000 and one eluting at the void volume. The component with an M_r of 150,000 was identified as consisting at least in part of EPA-α₂-antiplasmin complex since: 1) it reacted with antibodies against α₂-antiplasmin, but not with antibodies against the other known plasma protease inhibitors, and 2) formation of this component was strongly reduced in plasma specifically depleted in α₂-antiplasmin or when the active site of EPA was blocked. The component eluting at the void volume was identified as consisting at least in part of EPA-α₂-macroglobulin complex since: 1) it only reacted with antibodies against these two proteins and 2) was not formed in plasma depleted in α₂-macroglobulin or when the active site of EPA was blocked.

In purified systems α₂-antiplasmin inhibited one-chain EPA with a rate constant of 60 M^-1s^-1 and two-chain EPA with a rate constant of 130 M^-1s^-1, which corresponds to a t ½ in plasma of 180 min or 90 min, respectively. α₂-Macroglobulin inhibited one-chain EPA with a rate constant of 15 M^-1s^-1 and two-chain EPA with a rate constant of 30 M^-1s^-1, which corresponds to a t ½ plasma of 4 or 2 hrs.

All these findings taken together indicate that EPA is slowly neutralized in human plasma primarily by α₂-antiplasmin and to a lesser extent by α₂-macroglobulin. There appears to be no specific inhibitor in human plasma, which would inactivate EPA either rapidly or to a significant extent.

Keywords

Extrinsic (tissue-type) plasminogen activator - α₂-antiplasmin - α₂-macroglobulin - Antiactivator

• References

• 1 Aoki N, von Kaulla KN. Human serum plasminogen antiactivator: its distinction from antiplasmin. Am J Physiol 1971; 220: 1137-1145
• 2 Beattie AG, Ogston D, Bennett B, Douglas AS. Inhibitors of plasminogen activation in human blood. Br J Haemat 1976; 32: 135-143
• 3 Gurewich V, Hyde E, Lipinski B. The resistance of fibrinogen and soluble fibrin monomer in blood to degradation by a potent plasminogen activator derived from cadaver limbs. Blood 1975; 46: 555-565
• 4 Brakman P, Mohler ER, Astrup T. A group of patients with impaired plasma fibrinolytic system and selective inhibition of tissue activator induced fibrinolysis. Scand J Haematol 1966; 3: 389-398
• 5 Pandolfi M, Nilsson IM, Hedner U. Bilateral occlusion of the retinal veins in a patient with inhibition of fibrinolysis. Ann Ophtalmol 1970; 2: 481-485
• 6 Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem 1976; 69: 209-216
• 7 Moroi M, Aoki N. Isolation and characterization of alpha 2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis J Biol Chem 1976; 251: 5956-5965
• 8 Müllertz S, Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J 1976; 159: 545-553
• 9 Paraskevas M, Nilsson IM, Martinsson G. A method for determining serum inhibitors of plasminogen activation. Scand J Clin Lab Invest 1962; 14: 138-144
• 10 Bennett NB. A method for the quantitative assay of inhibitor of plasminogen activation in human serum. Thrombos Diathes haemorrh 1967; 17: 12-22
• 11 Clemmensen I, Christensen F. Inhibition of urokinase by complex formation with human α₂-antitrypsin. Biochim Biophys Acta 1976; 429: 591-599
• 12 Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-7041
• 13 Rijken DC. Biochemical and immunological characterization of plasminogen activator from human tissue. In: “Progress in Chemical Fibrinolysis and Thrombolysis, Vol.4”. Davidson JF, Cepelak V, Samama MM, Desnoyers PC. (eds) p 349-354 Churchill Livingstone; Edinburgh: 1979
• 14 Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096
• 15 McFarlane AG. Efficient trace-labelling of proteins with iodine. Nature 1958; 182: 53
• 16 Wiman B, Collen D. Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma. Eur J Biochem 1977; 78: 19-26
• 17 Harpel PC. Studies on human plasma α₂-macroglobulin-enzyme interactions. Evidence for proteolytic modification of the subunit chain structure J Exp Med 1973; 138: 508-517
• 18 Ganrot PO. Determination of α₂-macroglobulin as a trypsin esterase. Clin Chim Acta 1966; 14: 493-501
• 19 Alkjaersig N, Fletcher A. Metabolism of urokinase. In: »Thrombosis and Urokinase«. Paoletti R, Sherry S. eds Academic Press; London: 1977. p 129-141
• 20 Kominger C, Stassen JM, Collen D. Turnover of human extrinsic plasminogen activator in rabbits. Thromb Haemostas 1981; 46: 659-662